How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

922 results for

Common Clotting Pathway

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Common Clotting Pathway

Common Clotting Pathway Common Clotting Pathway Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Common Clotting Pathway Common (...) Clotting Pathway Aka: Common Clotting Pathway , Common Clotting Cascade II. Physiology: Pathway Factor Xa or: Factor V Inhibitors Protein C Protein S Medications: Direct Xa Inhibitors Factor II (Prothrombin) converted to IIa (Thrombin) cleaved cleaved to Fibrin Monomer Fibrin Monomer coalesced into Fibrin Polymer Factor XIII converted to XIIIa Fibrin polymer cross-linked Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Common

2018 FP Notebook

2. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results Full Text available with Trip Pro

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results Venous thromboembolism (VTE) is a common complication in newly diagnosed symptomatic multiple myeloma (NDMM) patients. We explored cellular and plasma hypercoagulability in NDMM patients to identify relevant biomarkers that can be used (...) biological signs of cellular and plasma hypercoagulability and endothelial cell activation. Procoagulant phospholipid clotting time (Procoagulant-PPL) was shorter, P-selectin levels lower and thrombin generation attenuated overall compared to healthy subjects. Longer Procoag-PPL®, lower endogenous thrombin potential (ETP), and higher levels of tissue factor pathway inhibitor (TFPI) were associated with VTE occurrence. Multivariate analysis showed that Procoag-PPL® and ETP were independent risk factors

2018 Blood cancer journal

3. Extended half-life clotting factor concentrates for treatment of haemophilia A and B

with prophylactic treatment, and has become less common. MSAC noted that approximately 80% of clotting factor use is for prophylaxis to prevent or reduce the frequency of bleeding episodes (i.e. standard care for patients with haemophilia). The remainder is on-demand use to control or prevent bleeding episodes. Treatment is provided by a haematologist, and most patients are treated at haemophilia treatment centres. MSAC noted that prophylactic dosing consists of standardised regimes to achieve target trough (...) Extended half-life clotting factor concentrates for treatment of haemophilia A and B 1 Public Summary Document Application No. 1511 – Extended half-life clotting factor concentrates for the treatment of haemophilia A and B Applicant: National Blood Authority Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application The application is to inform public

2018 Medical Services Advisory Committee

4. Blood & Clots Series: How do you stop warfarin for surgery?

Blood & Clots Series: How do you stop warfarin for surgery? Blood & Clots Series: How do you stop warfarin for surgery? - CanadiEM Blood & Clots Series: How do you stop warfarin for surgery? In , by Kerstin de Wit March 19, 2019 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed: Medical Expert, Scholar Case Description You are assessing a 76 year old lady who takes warfarin for stroke prevention because she had a mechanical aortic valve replacement 4 years ago (...) three months after the diagnosis of a new clot. Those with a recent history of venous thrombosis who require immediate surgery are considered high risk for recurrent venous thrombosis. Assessing the bleeding risk of the surgery or procedure In general, surgeries can be categorized into risk of blood loss. The risk may manifest in a variety of ways: for example an open aortic aneurysm repair could result in life threatening blood loss, massive transfusion and exsanguination with poor hemorrhage

2019 CandiEM

5. Clotting Pathway

Factor V Prothrombin Measures only common pathway V. Causes: Coagulation Disorder etiologies State ( ) ( ) Medication Induced ( ) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Clotting Pathway." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Blood Coagulation Factor (C0005789) Definition (NCI) Factors in the blood that are essential for blood (...) Clotting Pathway Clotting Pathway Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Clotting Pathway Clotting Pathway Aka: Clotting

2018 FP Notebook

6. Hepatitis C Virus Infection Care Pathway?A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group

Hepatitis C Virus Infection Care Pathway?A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group Fasiha Kanwal, 1 Bruce R. Bacon, 2 Lauren A. Beste, 3 Joel V. Brill, 4 Allen L. Gifford, 5 Stuart C. Gordon, 6 Michael A. Horberg, 7 Jacob G. Manthey, 8 Nancy Reau, 9 Vinod K. Rustgi, 10 and Zobair M. Younossi 11 1 Baylor (...) -AtlanticPermanenteResearchInstitute,KaiserPermanenteMid-AtlanticStates,Rockville; 8 AmericanGastroenterological Association, Bethesda, Maryland; 9 Rush University Medical Center, Chicago, Illinois; 10 Robert Wood Johnson School of Medicine, New Brunswick, New Jersey; and 11 Virginia Commonwealth University and Inova Fairfax Hospital, Falls Church, Virginia C hronic hepatitis Cvirus(HCV) infection isa common condition that affects more than 2.7 million individuals in the US. 1 New direct acting antiviral (DAA

2017 American Gastroenterological Association Institute

7. Perioperative Pathways: Enhanced Recovery After Surgery

and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Perioperative Pathways: Enhanced Recovery After Surgery ABSTRACT: Gynecologic surgery is very common: hysterectomy alone is one of the most frequently performed operating room procedures each year. It is well known that surgical stress induces a catabolic state that leads to increased cardiac demand, relative tissue hypoxia, increased insulin resistance, impaired (...) is a comprehensive program, and data demonstrate success when multiple components of the ERAS pathway are implemented together. The use of ERAS pathways should be strongly encouraged within institutions. Introduction Gynecologic surgery is very common—hysterectomy alone is one of the most frequently performed operating room procedures each year ( ). By using evidence-based protocols for perioperative and postoperative care, surgical stress can be reduced, healing optimized, and the patient experience improved

2018 American College of Obstetricians and Gynecologists

8. Common Clotting Pathway

Common Clotting Pathway Common Clotting Pathway Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Common Clotting Pathway Common (...) Clotting Pathway Aka: Common Clotting Pathway , Common Clotting Cascade II. Physiology: Pathway Factor Xa or: Factor V Inhibitors Protein C Protein S Medications: Direct Xa Inhibitors Factor II (Prothrombin) converted to IIa (Thrombin) cleaved cleaved to Fibrin Monomer Fibrin Monomer coalesced into Fibrin Polymer Factor XIII converted to XIIIa Fibrin polymer cross-linked Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Common

2015 FP Notebook

9. Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis. (Abstract)

, isocitrate dehydrogenase 1). These pathways define molecular subtypes of glioblastoma that express differential coagulomes. Moreover, single-cell sequencing of glioblastoma samples reveals a combinatorial rather than common profile of both subtype markers and coagulation-related genes. Based on these emerging observations, the authors suggest that cancers may operate as coagulant composites, where individual cells and their dominant populations express different procoagulant phenotypes, resulting (...) Oncogenes and Clotting Factors: The Emerging Role of Tumor Cell Genome and Epigenome in Cancer-Associated Thrombosis. There are emerging linkages between biological and genetic aspects of cancer progression and the mechanisms of cancer-associated thrombosis. It is argued that reciprocal influences between cancer cells, their associated vascular stroma, and the hemostatic system may shape the mechanism of coagulopathy. In this regard, glioblastoma multiforme offers a paradigm where the prevalent

2019 Seminars In Thrombosis And Hemostasis

10. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. (Abstract)

How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. The activated partial thromboplastin time (APTT) assay is a very common coagulation test, used for several reasons. The test is conventionally used for assessing the contact factor (intrinsic) pathway of blood coagulation, and thus for screening deficiencies (...) in this pathway, most typically factors VIII, IX, and XI. The APTT is also sensitive to contact factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen. The APTT may also be elevated in a variety of conditions, including liver disease, vitamin K deficiency, and disseminated intravascular coagulation. The APTT can also be used for monitoring unfractionated heparin (UFH) therapy, as well as for screening lupus anticoagulant (LA) or for assessing thrombosis risk. Which

2019 Seminars In Thrombosis And Hemostasis

11. Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state Full Text available with Trip Pro

Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state Activated factor V (FVa) and factor X (FXa) form prothrombinase, which converts prothrombin to thrombin. The α isoform of tissue factor (TF) pathway inhibitor (TFPI) dampens early procoagulant events, partly by interacting with FV. FV Leiden (FVL) is the most common genetic thrombophilia in Caucasians. Thrombosis risk is particularly elevated in women with FVL taking (...) , and this threshold is further reduced in situations of low TFPIα concentration. Individuals with FVL are likely prone to thrombosis in response to weak procoagulant stimuli that would not initiate blood clot formation in individuals with FV.

2017 Blood advances

12. Clotting Pathway

Factor V Prothrombin Measures only common pathway V. Causes: Coagulation Disorder etiologies State ( ) ( ) Medication Induced ( ) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Clotting Pathway." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Ontology: Blood Coagulation Factor (C0005789) Definition (NCI) Factors in the blood that are essential for blood (...) Clotting Pathway Clotting Pathway Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Clotting Pathway Clotting Pathway Aka: Clotting

2015 FP Notebook

13. Potentially Common Therapeutic Targets for Multiple Sclerosis and Ischemic Stroke Full Text available with Trip Pro

Potentially Common Therapeutic Targets for Multiple Sclerosis and Ischemic Stroke Ischemic stroke (IS) and multiple sclerosis (MS) are two pathologies of the central nervous system (CNS). At the first look, this appears to be the only similarity between the two diseases, as they seem quite different. Indeed IS has an acute onset compared to MS which develops chronically; IS is consecutive to blood clot migrating to cerebral blood vessels or decrease in cerebral blood flow following (...) atherosclerosis or decreases in cardiac output, whereas MS is an immune disease associated with neurodegeneration. However, both pathologies share similar pathologic pathways and treatments used in MS have been the object of studies in IS. In this mini-review we will discuss similarities between IS and MS on astrocytes and neuroinflammation hallmarks emphasizing the potential for treatments.

2018 Frontiers in physiology

14. Postpartum Nursing Care Pathway

Postpartum Nursing Care Pathway Introduction About the Maternal Postpartum Nursing Care Pathway 2 Who updated the Maternal Postpartum Nursing Care Pathway 2 Women-Centred Care 2 Referring to a Primary Health Care Provider (PHCP) 3 Referrals to Other Resources 3 Goals and Needs – Health Canada’s National Guidelines 3 Needs – World Health Organization 4 Timeframes 4 Maternal Physiological Stability 4 Postpartum Pain Scale (VAS) 5 Sedation Scale 5 Physiological Health Abdomen/Fundus 7 Pain 8 (...) Infant Feeding – Breastfeeding 39 Infant Feeding – Formula Feeding 42 Lifestyle Activities/Rest 43 Healthy Eating 45 Smoking and Use of Drugs/Substances 46 Safe Home Environment 48 Glossary of Abbreviations 49 References & Endnotes 49 Revision Committee 53 Perinatal Services BC Obstetrics Guideline 20 Postpartum Nursing Care Pathway March 2011 While every attempt has been made to ensure that the information contained herein is clinically accurate and current, Perinatal Services BC acknowledges

2011 British Columbia Perinatal Health Program

15. Saliva-Induced Clotting Captures Streptococci: Novel Roles for Coagulation and Fibrinolysis in Host Defense and Immune Evasion Full Text available with Trip Pro

Saliva-Induced Clotting Captures Streptococci: Novel Roles for Coagulation and Fibrinolysis in Host Defense and Immune Evasion Streptococcal pharyngitis is among the most common bacterial infections, but the molecular mechanisms involved remain poorly understood. Here we investigate the interactions among three major players in streptococcal pharyngitis: streptococci, plasma, and saliva. We find that saliva activates the plasma coagulation system through both the extrinsic and the intrinsic (...) pathways, entrapping the bacteria in fibrin clots. The bacteria escape the clots by activating host plasminogen. Our results identify a potential function for the intrinsic pathway of coagulation in host defense and a corresponding role for fibrinolysis in streptococcal immune evasion.Copyright © 2016 Wollein Waldetoft et al.

2016 Infection and immunity

16. Maternity Care Pathway

Maternity Care Pathway February 2010 B.C. Perinatal Health Program F502–4500 Oak Street Vancouver, BC Canada V6H 3N1 Tel: (604) 875-3737 www. bcphp.ca About The BC Maternity Care Pathway While every attempt has been made to ensure that the information contained herein is clinically accurate and current, the BC Perinatal Health Program acknowledges that many issues remain controversial, and therefore may be subject to practice interpretation. Contents Statement of Women-Centered Services (...) of the BC Maternity Care Enhancement Project (2004). This project called for the development of a woman-centered pathway to outline the care that a woman can expect to receive at each stage of her pregnancy. The purpose of the pathway is to inform all care providers of the current evidence- based recommendations for routine care in pregnancy to ensure that all women in BC receive the same high standard of care regardless of their residence or service provider or special needs. The guideline is intended

2010 British Columbia Perinatal Health Program

17. Comparative genomic study of arachnid immune systems indicates loss of βGRPs and the IMD pathway Full Text available with Trip Pro

, most studies have focused on insects leaving other major arthropod groups largely unexplored. Here, we annotate the immune-related genes of six arachnid genomes and present evidence for a conserved pattern of some immune genes, but also evolutionary changes in the arachnid immune system. Specifically, our results suggest that the family of recognition molecules of beta-1,3-glucanase-related proteins (βGRPs) and the genes from the immune deficiency (IMD) signalling pathway have been lost in a common (...) Comparative genomic study of arachnid immune systems indicates loss of βGRPs and the IMD pathway Analyses of arthropod genomes have shown that the genes in the different innate humoral immune responses are conserved. These genes encode proteins that are involved in immune signalling pathways that recognize pathogens and activate immune responses. These immune responses include phagocytosis, encapsulation of the pathogen and production of effector molecules for pathogen elimination. So far

2015 Journal of evolutionary biology

18. Hyperfibrinolysis is common in out-of-hospital cardiac arrest: Results from a prospective observational thromboelastometry study. (Abstract)

Hyperfibrinolysis is common in out-of-hospital cardiac arrest: Results from a prospective observational thromboelastometry study. Cardiocirculatory arrest (CCA) activates procoagulant pathways. It has also been reported to inhibit fibrinolysis, resulting in fibrin deposition and further impairment of blood flow. Until now, no studies have used whole-blood viscoelastic tests to characterize coagulation and the impact of fibrinolysis in out-of-hospital cardiac arrest (OHCA).Patient (...) patients. Prothrombin time index (PTI) was significantly lower and activated partial thromboplastin time (aPTT) was significantly prolonged in non-ROSC patients compared to ROSC patients. Clotting time (CT) in the extrinsically activated ROTEM test (EXTEM) was significantly longer in non-ROSC versus ROSC patients. For the remaining EXTEM parameters, there were no significant differences between ROSC and non-ROSC patients. Hyperfibrinolysis (maximum lysis>15% according to ROTEM test results

2012 Resuscitation

19. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

#notice-of-rights). Page 4 of 47This guideline replaces CG144. This guideline is the basis of QS29. Overview Overview This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. The guideline does (...) for DVT What is the clinical and cost effectiveness of clot removal using catheter-directed thrombolytic Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 28 of 47therapy or pharmacomechanical thrombolysis compared with standard anticoagulation therapy for the treatment of acute proximal DVT? [2012] [2012] Venous thromboembolic

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

20. Joint replacement (primary): hip, knee and shoulder

for primary elective hip replacement see surgical procedures for hip replacement in the NICE Pathway on joint replacement. Joint replacement (primary): hip, knee and shoulder (NG157) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 12 of 391.9 1.9 Procedures for primary elective shoulder Procedures for primary elective shoulder replacement replacement Shoulder replacement for osteoarthritis with no rotator cuff tear (...) or antiseptic agents to saline wound wash-out solution to reduce surgical site infections in people having primary elective joint replacement. The Joint replacement (primary): hip, knee and shoulder (NG157) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 28 of 39committee acknowledged that washing the wound with saline is common practice and is used to improve visibility of the operative site for the surgeon. They noted

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>